UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Targeting angiopoietin-2 as a novel treatment option for kidney fibrosis

Kidney international, 2022-10, Vol.102 (4), p.691-694

Samuel, Chrishan S.

2022

Volltextzugriff (PDF)

Electrophysiological, Electroanatomical, and Structural Remodeling of the Atria as Consequences of Sustained Obesity

Journal of the American College of Cardiology, 2015-07, Vol.66 (1), p.1-11

2015

Volltextzugriff (PDF)

Anti-inflammatory effects of adult stem cells in sustained lung injury: a comparative study

PloS one, 2013-08, Vol.8 (8), p.e69299

2013

Volltextzugriff (PDF)

Relaxin as an anti-fibrotic treatment: Perspectives, challenges and future directions

Biochemical pharmacology, 2022-03, Vol.197, p.114884-114884, Article 114884

2022

Volltextzugriff (PDF)

Inflammasomes-A Molecular Link for Altered Immunoregulation and Inflammation Mediated Vascular Dysfunction in Preeclampsia

International journal of molecular sciences, 2020-02, Vol.21 (4), p.1406

2020

Volltextzugriff (PDF)

Functional crosstalk between angiotensin receptors (types 1 and 2) and relaxin family peptide receptor 1 (RXFP1): Implications for the therapeutic targeting of fibrosis

British journal of pharmacology, 2024-07, Vol.181 (14), p.2302-2318

2024

Volltextzugriff (PDF)

Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension

Cardiovascular research, 2019-03, Vol.115 (4), p.776-787

2019

Volltextzugriff (PDF)

Preclinical rodent models of cardiac fibrosis

British journal of pharmacology, 2022-03, Vol.179 (5), p.882-899

2022

Volltextzugriff (PDF)

Immune Mechanisms and Related Targets for the Treatment of Fibrosis in Various Organs

Current molecular medicine, 2022-01, Vol.22 (3), p.240-249

2022

Volltextzugriff (PDF)

Relaxin signals through a RXFP1-pERK-nNOS-NO-cGMP-dependent pathway to up-regulate matrix metalloproteinases: the additional involvement of iNOS

PloS one, 2012-08, Vol.7 (8), p.e42714-e42714

2012

Volltextzugriff (PDF)

Serelaxin inhibits the profibrotic TGF‐β1/IL‐1β axis by targeting TLR‐4 and the NLRP3 inflammasome in cardiac myofibroblasts

The FASEB journal, 2019-12, Vol.33 (12), p.14717-14733

2019

Volltextzugriff (PDF)

Human Umbilical Cord Mesenchymal Stem Cells Reduce Fibrosis of Bleomycin-Induced Lung Injury

The American journal of pathology, 2009-07, Vol.175 (1), p.303-313

2009

Volltextzugriff (PDF)

Enhancing the Therapeutic Potential of Mesenchymal Stromal Cell-Based Therapies with an Anti-Fibrotic Agent for the Treatment of Chronic Kidney Disease

International journal of molecular sciences, 2022-05, Vol.23 (11), p.6035

2022

Volltextzugriff (PDF)

A Lipidated Single-B-Chain Derivative of Relaxin Exhibits Improved In Vitro Serum Stability without Altering Activity

International journal of molecular sciences, 2023-04, Vol.24 (7), p.6616

2023

Volltextzugriff (PDF)

The efficacy and safety of pinocembrin in a sheep model of bleomycin-induced pulmonary fibrosis

PloS one, 2021-12, Vol.16 (12), p.e0260719-e0260719

2021

Volltextzugriff (PDF)

Determination of Interstitial Collagen Deposition and Related Topography Using the Second Harmonic Generation-Based HistoIndex Platform

Methods in molecular biology (Clifton, N.J.), 2023, Vol.2664, p.173

2023

Volltextzugriff (PDF)

Relaxin and extracellular matrix remodeling: Mechanisms and signaling pathways

Molecular and cellular endocrinology, 2019-05, Vol.487, p.59-65

2019

Volltextzugriff (PDF)

Relaxin Inhibits the Cardiac Myofibroblast NLRP3 Inflammasome as Part of Its Anti-Fibrotic Actions via the Angiotensin Type 2 and ATP (P2X7) Receptors

International journal of molecular sciences, 2022-07, Vol.23 (13), p.7074

2022

Volltextzugriff (PDF)

Serelaxin enhances the therapeutic effects of human amnion epithelial cell‐derived exosomes in experimental models of lung disease

British journal of pharmacology, 2019-07, Vol.176 (13), p.2195-2208

2019

Volltextzugriff (PDF)

IL-4 and IL-13 induce equivalent expression of traditional M2 markers and modulation of reactive oxygen species in human macrophages

Scientific reports, 2023-11, Vol.13 (1), p.19589-19589, Article 19589

2023

Volltextzugriff (PDF)

The involvement of the Wnt/β-catenin signaling cascade in fibrosis progression and its therapeutic targeting by relaxin

Biochemical pharmacology, 2024-05, Vol.223, p.116130, Article 116130

2024

Volltextzugriff (PDF)

Targeting the NLRP3 inflammasome to treat cardiovascular fibrosis

Pharmacology & therapeutics (Oxford), 2020-05, Vol.209, p.107511-107511, Article 107511

2020

Volltextzugriff (PDF)

Serelaxin as a novel therapeutic opposing fibrosis and contraction in lung diseases

Pharmacology & therapeutics (Oxford), 2018-07, Vol.187, p.61-70

2018

Volltextzugriff (PDF)

Human mesenchymal stem cells alter macrophage phenotype and promote regeneration via homing to the kidney following ischemia-reperfusion injury

American journal of physiology. Renal physiology, 2014-05, Vol.306 (10), p.F1222-F1235

2014

Volltextzugriff (PDF)

Intranasal administration of mesenchymoangioblast‐derived mesenchymal stem cells abrogates airway fibrosis and airway hyperresponsiveness associated with chronic allergic airways disease

The FASEB journal, 2017-09, Vol.31 (9), p.4168-4178

2017

Volltextzugriff (PDF)

1 – 25 von 230

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(215)
Mit Volltextzugriff
(208)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Targeting angiopoietin-2 as a novel treatment option for kidney fibrosis

Electrophysiological, Electroanatomical, and Structural Remodeling of the Atria as Consequences of Sustained Obesity

Anti-inflammatory effects of adult stem cells in sustained lung injury: a comparative study

Relaxin as an anti-fibrotic treatment: Perspectives, challenges and future directions

Inflammasomes-A Molecular Link for Altered Immunoregulation and Inflammation Mediated Vascular Dysfunction in Preeclampsia

Functional crosstalk between angiotensin receptors (types 1 and 2) and relaxin family peptide receptor 1 (RXFP1): Implications for the therapeutic targeting of fibrosis

Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension

Preclinical rodent models of cardiac fibrosis

Immune Mechanisms and Related Targets for the Treatment of Fibrosis in Various Organs

Relaxin signals through a RXFP1-pERK-nNOS-NO-cGMP-dependent pathway to up-regulate matrix metalloproteinases: the additional involvement of iNOS

Serelaxin inhibits the profibrotic TGF‐β1/IL‐1β axis by targeting TLR‐4 and the NLRP3 inflammasome in cardiac myofibroblasts

Human Umbilical Cord Mesenchymal Stem Cells Reduce Fibrosis of Bleomycin-Induced Lung Injury

Enhancing the Therapeutic Potential of Mesenchymal Stromal Cell-Based Therapies with an Anti-Fibrotic Agent for the Treatment of Chronic Kidney Disease

A Lipidated Single-B-Chain Derivative of Relaxin Exhibits Improved In Vitro Serum Stability without Altering Activity

The efficacy and safety of pinocembrin in a sheep model of bleomycin-induced pulmonary fibrosis

Determination of Interstitial Collagen Deposition and Related Topography Using the Second Harmonic Generation-Based HistoIndex Platform

Relaxin and extracellular matrix remodeling: Mechanisms and signaling pathways

Relaxin Inhibits the Cardiac Myofibroblast NLRP3 Inflammasome as Part of Its Anti-Fibrotic Actions via the Angiotensin Type 2 and ATP (P2X7) Receptors

Serelaxin enhances the therapeutic effects of human amnion epithelial cell‐derived exosomes in experimental models of lung disease

IL-4 and IL-13 induce equivalent expression of traditional M2 markers and modulation of reactive oxygen species in human macrophages

The involvement of the Wnt/β-catenin signaling cascade in fibrosis progression and its therapeutic targeting by relaxin

Targeting the NLRP3 inflammasome to treat cardiovascular fibrosis

Serelaxin as a novel therapeutic opposing fibrosis and contraction in lung diseases

Human mesenchymal stem cells alter macrophage phenotype and promote regeneration via homing to the kidney following ischemia-reperfusion injury

Intranasal administration of mesenchymoangioblast‐derived mesenchymal stem cells abrogates airway fibrosis and airway hyperresponsiveness associated with chronic allergic airways disease

Suchergebnisse filtern